Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17709139 | 0.90 | CYP19A1 (0.82) | CYP19A1MAOBCYP3A4PTPN1 | |
| SCHEMBL17709142 | 0.90 | CYP19A1 (0.82) | CYP19A1MAOBCYP3A4PTPN1 | |
| SCHEMBL30499387 | 0.90 | ABCB1 (0.82) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL29020378 | 0.90 | ABCB1 (0.82) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL17708871 | 0.88 | AR (0.67) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL1820849 | 0.88 | AR (0.67) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL4951516 | 0.88 | CYP19A1 (0.73) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL4953726 | 0.86 | AR (0.81) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL4362380 | 0.86 | AR (0.81) | CYP19A1ARABCG2ABCB1NPC1 | |
| SCHEMBL28186099 | 0.85 | ABCB1 (0.67) | CYP19A1ARABCG2ABCB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-1412343-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | CYP19A1 2036/4885AR 965/4885ABCG2 961/4885 |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | CYP19A1 2119/4885AR 3262/4885ABCG2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.